Canaccord Genuity Group Lowers Stoke Therapeutics (NASDAQ:STOK) Price Target to $20.00

Stoke Therapeutics (NASDAQ:STOK) had its target price decreased by Canaccord Genuity Group from $21.00 to $20.00 in a report released on Tuesday morning, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other research firms also recently weighed in on STOK. Needham & Company LLC restated a buy rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Monday. TD Cowen upgraded Stoke Therapeutics from a market perform rating to an outperform rating in a report on Tuesday, March 26th. Wedbush upped their price target on Stoke Therapeutics from $13.00 to $17.00 and gave the stock an outperform rating in a research note on Tuesday, March 26th. JPMorgan Chase & Co. raised their price objective on Stoke Therapeutics from $6.00 to $13.00 and gave the company a neutral rating in a research note on Tuesday, March 26th. Finally, HC Wainwright reiterated a buy rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics has a consensus rating of Moderate Buy and an average price target of $20.57.

Stoke Therapeutics Price Performance

Shares of STOK opened at $11.94 on Tuesday. The company has a market capitalization of $622.31 million, a price-to-earnings ratio of -5.04 and a beta of 0.82. The business’s 50-day moving average is $10.23 and its 200-day moving average is $6.68. Stoke Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $16.40.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.02. The company had revenue of $2.80 million during the quarter, compared to analyst estimates of $3.70 million. Equities research analysts expect that Stoke Therapeutics will post -2.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the transaction, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the sale, the chief executive officer now owns 69,350 shares of the company’s stock, valued at approximately $423,035. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen J. Tulipano sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the transaction, the chief financial officer now owns 20,746 shares in the company, valued at $126,550.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,622,741 shares of company stock valued at $41,935,115. 11.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently made changes to their positions in STOK. SG Americas Securities LLC acquired a new position in Stoke Therapeutics during the 3rd quarter valued at about $53,000. Bank of New York Mellon Corp lifted its holdings in Stoke Therapeutics by 2.8% in the third quarter. Bank of New York Mellon Corp now owns 107,254 shares of the company’s stock valued at $423,000 after buying an additional 2,926 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Stoke Therapeutics by 9.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock valued at $576,000 after acquiring an additional 12,478 shares during the last quarter. Dorsey & Whitney Trust CO LLC acquired a new stake in Stoke Therapeutics during the 3rd quarter worth $43,000. Finally, Trexquant Investment LP raised its position in shares of Stoke Therapeutics by 166.9% during the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after acquiring an additional 79,785 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.